Paper34838121
Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.
Lu JC and 14 others. J Hematol Oncol, 2021. Cited by 145 papers, by iCite.
Cite this record
ConductScience Library. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. Papers, record 34838121. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34838121
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenosine | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Liver Neoplasms | Major topic |
| Cell Line, Tumor | |
| Humans | |
| Signal Transduction |
Source PubMed
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25403716 | Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. | Cancer Immunol Res | 2015 | https://conductscience.org/library/papers/25403716 | PubMed |
| 2 | 31404607 | Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. | Semin Cancer Biol | 2019 | https://conductscience.org/library/papers/31404607 | PubMed |
| 3 | 17077301 | HIF-dependent induction of adenosine A2B receptor in hypoxia. | FASEB J | 2006 | https://conductscience.org/library/papers/17077301 | PubMed |
| 4 | 32641297 | Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia. | Cancer Discov | 2020 | https://conductscience.org/library/papers/32641297 | PubMed |
| 5 | 31790344 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/31790344 | PubMed |
| 6 | 30971294 | CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis. | J Hematol Oncol | 2019 | https://conductscience.org/library/papers/30971294 | PubMed |
| 7 | 25891174 | Pembrolizumab for the treatment of non-small-cell lung cancer. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25891174 | PubMed |
| 8 | 30735636 | The Landscape of Circular RNA in Cancer. | Cell | 2019 | https://conductscience.org/library/papers/30735636 | PubMed |
| 9 | 29059149 | Targeting immunosuppressive adenosine in cancer. | Nat Rev Cancer | 2017 | https://conductscience.org/library/papers/29059149 | PubMed |
| 10 | 30755690 | The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. | Nat Rev Cancer | 2019 | https://conductscience.org/library/papers/30755690 | PubMed |
| 11 | 23724846 | Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23724846 | PubMed |
| 12 | 33985545 | CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity. | Mol Cancer | 2021 | https://conductscience.org/library/papers/33985545 | PubMed |
| 13 | 27899277 | Protective role of hypoxia-inducible factor-1α-dependent CD39 and CD73 in fulminant acute liver failure. | Toxicol Appl Pharmacol | 2017 | https://conductscience.org/library/papers/27899277 | PubMed |
| 14 | 25127858 | Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors. | J Immunol | 2014 | https://conductscience.org/library/papers/25127858 | PubMed |
| 15 | 32430013 | Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. | Mol Cancer | 2020 | https://conductscience.org/library/papers/32430013 | PubMed |
| 16 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 17 | 32503591 | Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment. | J Hematol Oncol | 2020 | https://conductscience.org/library/papers/32503591 | PubMed |
| 18 | 30735634 | Widespread and Functional RNA Circularization in Localized Prostate Cancer. | Cell | 2019 | https://conductscience.org/library/papers/30735634 | PubMed |
| 19 | 19349973 | Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. | Nat Biotechnol | 2009 | https://conductscience.org/library/papers/19349973 | PubMed |
| 20 | 32640203 | Cancer Cells Don't Live Alone: Metabolic Communication within Tumor Microenvironments. | Dev Cell | 2020 | https://conductscience.org/library/papers/32640203 | PubMed |
Cited by111
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 145 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42947178 | Targeting circular RNAs to overcome therapeutic resistance in liver cancer: from mechanisms to clinical prospects. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42947178 | PubMed |
| 42909923 | Portal Vein Tumor Thrombus in Hepatocellular Carcinoma: An Immune Sanctuary Driving Immune Exclusion and Therapeutic Resistance. | Liver Cancer | 2026 | https://conductscience.org/library/papers/42909923 | PubMed |
| 42835409 | Functional heterogeneity of exosomes in hepatocellular carcinoma (Review). | Exp Ther Med | 2026 | https://conductscience.org/library/papers/42835409 | PubMed |
| 42819771 | Immune escape in portal vein tumor thrombus: an intravascular tumor-immune niche framework for hepatocellular carcinoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42819771 | PubMed |
| 42757479 | Exosomal circular RNAs in the tumor immune microenvironment: From regulatory mechanisms to therapeutic opportunities and translational hurdles (Review). | Int J Mol Med | 2026 | https://conductscience.org/library/papers/42757479 | PubMed |
| 42707968 | Adenosine signaling in tumor immune escape: metabolic checkpoints, myeloid suppression, and combination immunotherapy. | Front Oncol | 2026 | https://conductscience.org/library/papers/42707968 | PubMed |
| 42395637 | Emerging role of proteomics in advancing diagnosis, prognosis, and treatment of liver cancer. | Liver Res | 2026 | https://conductscience.org/library/papers/42395637 | PubMed |
| 42321851 | Extracellular vesicles in solid tumors: from tumor ecology to engineered therapeutics. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42321851 | PubMed |
| 42286649 | Circular RNAs in tumor biology and immunology: molecular mechanisms and therapeutic implications. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42286649 | PubMed |
| 42196608 | Regulatory T Cells in Hepatocellular Carcinoma: Spatial Niches, Biomarkers, and Clinical Implications. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196608 | PubMed |
| 42112389 | Roles of exosomal non-coding RNAs in osteoarthritis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42112389 | PubMed |
| 42074315 | Novel Insights into the Role of circRNAs in Cancer Immunotherapy Resistance and Clinical Implications. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42074315 | PubMed |
| 42051530 | Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategies. | Front Immunol | 2026 | https://conductscience.org/library/papers/42051530 | PubMed |
| 42036237 | [Research progress on poor response, resistance mechanisms, and influencing factors of immunotherapy for hepatocellular carcinoma]. | Zhonghua Gan Zang Bing Za Zhi | 2026 | https://conductscience.org/library/papers/42036237 | PubMed |
| 41832910 | The controversial role of metabolic reprogramming in anti-tumor therapy resistance. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41832910 | PubMed |
| 41763068 | A2AR as a key target for immune microenvironment remodeling in prostate cancer. | Transl Oncol | 2026 | https://conductscience.org/library/papers/41763068 | PubMed |
| 41673369 | HBV reprograms the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic implications. | Clin Exp Med | 2026 | https://conductscience.org/library/papers/41673369 | PubMed |
| 41662387 | MicroRNA-488-3p-loaded engineered exosomes inhibit proliferation, migration and invasion of hepatocellular carcinoma by targeting SEC61G. | PLoS One | 2026 | https://conductscience.org/library/papers/41662387 | PubMed |
| 41514551 | Mechanisms of Immune Checkpoint Inhibitor Resistance in Hepatocellular Carcinoma and Strategies for Reversal. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41514551 | PubMed |
| 41416448 | Exosomal circRNAs in hepatocellular carcinoma: Implications for the development and therapeutic resistance of hepatocellular carcinoma (Review). | Int J Oncol | 2026 | https://conductscience.org/library/papers/41416448 | PubMed |
Genes30
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34838121
GET https://conductscience.org/api/papers/v1/34838121/references?page=2